Compare FSTR & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | SGHT |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 235.0M |
| IPO Year | 1995 | 2021 |
| Metric | FSTR | SGHT |
|---|---|---|
| Price | $41.83 | $4.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $32.00 | $9.08 |
| AVG Volume (30 Days) | 96.8K | ★ 180.9K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $540,009,000.00 | $77,363,000.00 |
| Revenue This Year | $5.12 | $11.67 |
| Revenue Next Year | $2.78 | $10.39 |
| P/E Ratio | $300.07 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $19.20 | $3.11 |
| 52 Week High | $43.06 | $9.24 |
| Indicator | FSTR | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 46.25 |
| Support Level | $25.81 | $3.34 |
| Resistance Level | $42.76 | $5.25 |
| Average True Range (ATR) | 1.59 | 0.31 |
| MACD | -0.09 | -0.09 |
| Stochastic Oscillator | 74.56 | 26.11 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.